Sunday, May 31, 2015

AMGN: Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple Myeloma

New alert via PocketInfo for AMGN:

Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple Myeloma

Press Releases: http://www.amgen.com/media/pr.jsp
SEC Filings: http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-sec
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8

No comments:

Post a Comment